Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis

被引:3
|
作者
Edmunds, Kim [1 ]
Scuffham, Paul [2 ]
Newton, Robert U. [3 ]
Galvao, Daniel A. [3 ]
Tuffaha, Haitham [1 ]
机构
[1] Univ Queensland, Ctr Business & Econ Hlth, Brisbane, Qld 4072, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Australia
[3] Edith Cowan Univ, Exercise Med Res Inst, Joondalup, Australia
关键词
Economic evaluation; Cost-utility analysis; Exercise medicine; Physical activity; Prostate cancer; Androgen deprivation therapy; QUALITY-OF-LIFE; OLDER-PEOPLE; ANDROGEN DEPRIVATION; ECONOMIC-EVALUATION; CONTROLLED-TRIAL; HEALTH; PROGRAM; GUIDELINES; RADIATION; SURVIVORS;
D O I
10.1007/s00520-022-06900-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Men who receive androgen deprivation therapy (ADT) for prostate cancer (PCa) are a vulnerable falls population due to the side effects of treatment. The purpose of this paper is to determine the cost-effectiveness of exercise in preventing falls and fractures for this high-risk population in Australia. Methods A decision analytic model was constructed to evaluate the cost utility of an exercise intervention compared to usual care from a health system perspective. The intervention comprised two 1-h sessions of supervised exercise per week over 1 year for men with non-metastatic PCa receiving curative radiation therapy and ADT. A Markov model simulated the transition between five health states: (1) at risk of falling; (2) at recurrent risk of falling; (3) fracture (minor or major); (4) non-fracture injury (minor or major); and (5) death. Model inputs including transition probabilities and utility scores were obtained from published meta-analyses, and costs were drawn from Australian data sources (e.g. Medical Benefits Schedule). The model time horizon was 3 years, and costs and effects were discounted at 5% annual rate. Costs and quality-adjusted life years (QALYs) were aggregated and compared between the intervention and control to calculate incremental net monetary benefit (iNMB). Uncertainty in the results was explored using deterministic and probabilistic sensitivity analyses (PSA). Results At a willingness-to-pay of AU$50,000 per QALY, the exercise intervention dominated, as it was less costly and more effective than usual care. The iNMB was $3010 per patient. The PSA showed a 58% probability the intervention was cost-effective. Conclusion This is the first modelled economic evaluation of exercise for men with PCa. Our results suggest supervised exercise is cost-effective in reducing the risks of falls and fractures in this population.
引用
收藏
页码:5037 / 5046
页数:10
相关论文
共 50 条
  • [21] The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
    Adam Fridhammar
    Ulrika Axelsson
    Ulf Persson
    Anders Bjartell
    Carl A. K. Borrebaeck
    PharmacoEconomics - Open, 2021, 5 : 77 - 88
  • [22] Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer
    Yufan Wang
    Alexandra L McCarthy
    Haitham Tuffaha
    Supportive Care in Cancer, 2023, 31
  • [23] Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer
    Wang, Yufan
    McCarthy, Alexandra
    Tuffaha, Haitham
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 60 - 60
  • [24] A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF ADVANCED HORMONE-DEPENDENT PROSTATE CANCER IN SCOTLAND
    Fisher, D.
    Brereton, N. J.
    Kildegaard Nielsen, S.
    Tate, E.
    VALUE IN HEALTH, 2011, 14 (07) : A452 - A452
  • [25] Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer
    Wang, Yufan
    McCarthy, Alexandra L.
    Tuffaha, Haitham
    SUPPORTIVE CARE IN CANCER, 2023, 31 (07)
  • [26] The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
    Fridhammar, Adam
    Axelsson, Ulrika
    Persson, Ulf
    Bjartell, Anders
    Borrebaeck, Carl A. K.
    PHARMACOECONOMICS-OPEN, 2021, 5 (01) : 77 - 88
  • [27] COST-UTILITY ANALYSIS IN UROLOGY
    Fero, Katherine
    Sharma, Vidit
    Lec, Patrick
    Saigal, Christopher
    Chamie, Karim
    JOURNAL OF UROLOGY, 2021, 206 : E435 - E436
  • [28] Cost-utility analysis for UTIs
    Schaefer, SE
    JOURNAL OF FAMILY PRACTICE, 1997, 44 (04): : 329 - 329
  • [29] Modelled cost-effectiveness and cost-utility analysis of various treatment strategies in osteoporotic postmenopausal women in Poland
    Orlewska, E
    Lis, J
    VALUE IN HEALTH, 2002, 5 (06) : 477 - 477
  • [30] Cost-utility analysis in schizophrenia
    Awad, AG
    Voruganti, LP
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 22 - 28